Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Home Research Research Publication Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators.

Ophthalmology. 2019 May;126(5):723-734. doi: 10.1016/j.ophtha.2018.11.025. Epub 2018 Nov 29.

PMID: 30502372 IF 7.732

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

(08) 9381 0777

carecentre@lei.org.au

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.

Need any help?

Request an appointment